- searching for studies which match the preset criteria in a systematic manner
- sort all retrieved articles (included or excluded) and assess the risk of bias for each included study
- each study is coded with preset form, either qualitatively or quantitatively synthesize data.
- place results of synthesis into context, strengths and weaknesses of the studies
- report provides description of methods and results in a clear and transparent manner
Source: Foster, M. (2018). Systematic reviews service: Introduction to systematic reviews. Retrieved September 18, 2018, from
- << Previous: What is a Systematic Review (SR)?
- Next: Framing a Research Question >>
- Last Updated: May 8, 2024 1:44 PM
- URL: https://lib.guides.umd.edu/SR
![stages in literature review process Sac State Library](https://library.csus.edu/themes/university_library/images/SacStateLibraryLogo.png)
- My Library Account
- Articles, Books & More
- Course Reserves
- Site Search
- Advanced Search
- Sac State Library
- Research Guides
- Writing a Literature Review
- 6 Stages to Writing a Literature Review
- What is a Literature Review?
- Literature Review Examples
- Organizing Your Literature Review
- Managing your Citations
- Further Reading on Lit Reviews
Academic Phrasebank
- Last Updated: Jun 6, 2024 9:36 AM
- URL: https://csus.libguides.com/litreview
'Babbling' and 'hoarse': Biden's debate performance sends Democrats into a panic
ATLANTA — President Joe Biden was supposed to put the nation’s mind at ease over his physical and mental capacity with his debate showing Thursday night.
But from the onset of the debate, Biden, 81, seemingly struggled even to talk, mostly summoning a weak, raspy voice. In the opening minutes, he repeatedly tripped over his words, misspoke and lost his train of thought.
In one of the most notable moments, Biden ended a rambling statement that lacked focus by saying, “We finally beat Medicare,” before moderators cut him off and transitioned back to former President Donald Trump.
While Biden warmed up and gained more of a rhythm as the debate progressed, he struggled to land a punch against Trump, much less fact-check everything Trump said as he unleashed a torrent of bad information.
Trump also pounced on Biden, saying at one point that he didn’t understand what Biden had just said with regard to the border.
“I don’t know if he knows what he said, either,” Trump said.
Nearly an hour into the debate, a Biden aide and others familiar with his situation offered up an explanation for his hoarseness: He has a cold.
But there were problems aside from the shakiness of Biden's voice. When he wasn't talking, he often stared off into the distance. Trump frequently steamrolled over Biden, accusing him of being a criminal and of peddling misinformation — many times without a response from Biden, though he did fire back with a handful of one-liners throughout.
The Biden campaign acknowledged that the debate would be a critical moment in the election, with officials hoping it could shake up the race to his benefit. Most polls have found the race to be neck and neck, with razor-thin margins that have moved negligibly for months, even after a New York jury found Trump guilty on 34 felony counts .
Questions about Biden’s age and frailty have dragged down his polling numbers for months. The public concerns are exacerbated by deceptively edited videos , some of which have gone viral, that cut off relevant parts of an event, making it appear as if Biden is wandering or confused. This was Biden’s first opportunity since the State of the Union speech to dispel that narrative.
Instead of a new beginning, many Democrats saw it as a moment for panic.
“Democrats just committed collective suicide,” said a party strategist who has worked on presidential campaigns. “Biden sounds hoarse, looks tired and is babbling. He is reaffirming everything voters already perceived. President Biden can’t win. This debate is a nail in the political coffin.”
“It’s hard to argue that we shouldn’t nominate someone else,” a Democratic consultant who works on down-ballot races said.
Biden did ramp up as the debate progressed.
“Only one of us is a convicted felon, and I’m looking at him,” Biden said to Trump. That was one moment that tested particularly well in the Biden campaign's internal real-time polling at the time of the debate, according to a person familiar with the polling.
An aide said that it was “not an ideal start” for Biden at the beginning of the debate but that there was “no mass panic” at the campaign headquarters in Delaware.
The muting of the candidates' microphones at the debate, a stipulation both campaigns agreed to before the debate, added a new dimension to the faceoff. The first Biden-Trump match-up in 2020 was marked by repeated interruptions by Trump, leading to moments of frustration for Biden.
“Will you shut up, man?” Biden complained at that first Cleveland debate.
Reaction pours in
“I’m thinking the Democrats are thinking about who the Barry Goldwater is who can walk in tomorrow and tell the president he needs to step aside,” said Ben Proto, chairman of the Connecticut Republican Party.
In 1974, after key Watergate tapes were made public, Sen. Barry Goldwater, R-Ariz., went to see President Richard Nixon alongside other prominent lawmakers, telling Nixon that he would be convicted by the Senate and that he should step aside — which he did.
Biden’s campaign defended his performance, saying he offered a “positive and winning vision” for America.
“On the other side of the stage was Donald Trump, who offered a dark and backwards window into what America will look like if he steps foot back in the White House: a country where women are forced to beg for the health care they need to stay alive. A country that puts the interests of billionaires over working people,” Biden campaign chair Jen O’Malley Dillon said in a statement. “And a former president who not once, not twice, but three times, failed to promise he would accept the results of a free and fair election this November.”
Some Democrats also defended Biden presidency more broadly after the debate, pointing to his policies over Trump's.
"One thing this debate won’t change is Trump’s base instinct to sell out anyone to make a quick buck or put his own image on a steak, golf course or even the Holy Bible," said Brandon Weathersby, a spokesman with the pro-Biden American Bridge 21st Century super PAC. "Trump puts himself first every time, and that won’t change if he becomes president again."
Trump, meanwhile, has fended off his own questions over whether he’s diminished by age, including his struggles to stay on topic and his meandering when he’s speaking . Biden has posited that Trump “snapped” after his 2020 election loss and is unstable, which he aired again Thursday night.
Trump often gave his typical rambling responses and seemed at times to make up factoids and figures.
“During my four years, I had the best environmental numbers ever, and my top environmental people gave me that statistic just before I walked on the stage, actually,” Trump said.
Trump also said he would lower insulin prices for seniors, but it was Biden who signed legislation in 2022 that lowered out-of-pocket costs for people on Medicare to $35 a month and covered all insulin products.
Setting the stage for the fall
The first debate during the 2020 election cycle was in early September, meaning the first 2024 general election debate was significantly earlier than usual — more than two months ahead of Labor Day, which is often seen as the point when most voters start to pay attention to presidential contests.
“Debates move numbers,” said Matt Gorman, a longtime Republican strategist who worked for presidential campaign of Sen. Tim Scott of South Carolina. “And with this so early — and the next one not until September — you’re stuck with the narrative for four long months.
“And one and the other’s performance will set the tone for the next one,” he added.
For months, Trump’s team has been hammering Biden’s mental acuity, a strategy that is at odds with how campaigns generally handle the lead-up to debates, when they try to build up opponents as deft debaters to set expectations.
The expectations for Biden were low, and by almost all estimates he was unable to clear them.
“Biden just had to beat himself; unfortunately the stumbling and diminished Joe Biden the world has come to know made Trump look competent and energetic,” said a former Trump campaign official who isn’t working for his campaign this year. “I expect there will be some loud calls from Democrats for a change on the top of the ticket.”
“The floor for Biden was so low,” the person added. “After Biden’s debate performance, it seems the floor is 6 feet under.”
The 90-minute debate hit on a wide variety of topics, but many of the most dominant themes were centered on those that have been most prominent on the campaign trail over the past few months.
Trump hit Biden on two big policy fights that have stubbornly dogged his campaign: immigration and inflation.
Since Biden took office, 15 million jobs have been created and the unemployment rate sits at a relatively low 4%, but prices for consumer goods have remained high, and they provided a consistent line of attack from the Trump campaign and Republicans more broadly.
In one heated exchange, Trump point-blank said “he caused the inflation.” Biden said in response there was less inflation under Trump because he tanked the economy.
“There was no inflation when I came into office,” Biden said before that rejoinder — a quote Republicans quickly used as evidence that all of the current price hikes happened on Biden’s watch.
Trump continued to attack Biden over his border policies, which his campaign has used as one of its biggest lines of attack throughout the campaign. That often including amplifying each time an undocumented migrant commits a crime even though the data doesn’t support the idea of a migrant crime wave .
“ We have a border that is the most dangerous place anywhere in the world,” Trump said.
Earlier this year, Trump used his influence over congressional Republicans to block a bipartisan border deal that Biden supported.
Biden also tried to land a punch about Jan. 6, trying to build on the oft-discussed idea that Trump’s returning to the White House would be a threat to democracy.
“He encouraged those folks to go up to Capitol Hill,” Biden said. “He sat there for three hours being begged by his vice president and many colleagues on the Republican side to do something.”
Trump deflected, arguing the Biden should be “ashamed” for arresting those who participated in the attempted insurrection.
![stages in literature review process](https://media-cldnry.s-nbcnews.com/image/upload/t_focal-60x60,f_auto,q_auto:best/newscms/2023_04/3591706/korecki_21_76_copy_copy.png)
Natasha Korecki is a senior national political reporter for NBC News.
![stages in literature review process](https://media-cldnry.s-nbcnews.com/image/upload/t_focal-60x60,f_auto,q_auto:best/newscms/2024_24/3651229/240610-matt-dixon-mn-1410.jpg)
Matt Dixon is a senior national politics reporter for NBC News, based in Florida.
![stages in literature review process](https://media-cldnry.s-nbcnews.com/image/upload/t_focal-60x60,f_auto,q_auto:best/newscms/2024_26/3653033/230226-jonathan-allen.jpg)
Jonathan Allen is a senior national politics reporter for NBC News, based in Washington.
An official website of the United States Government
- Kreyòl ayisyen
- Search Toggle search Search Include Historical Content - Any - No Include Historical Content - Any - No Search
- Menu Toggle menu
- INFORMATION FOR…
- Individuals
- Business & Self Employed
- Charities and Nonprofits
- International Taxpayers
- Federal State and Local Governments
- Indian Tribal Governments
- Tax Exempt Bonds
- FILING FOR INDIVIDUALS
- How to File
- When to File
- Where to File
- Update Your Information
- Get Your Tax Record
- Apply for an Employer ID Number (EIN)
- Check Your Amended Return Status
- Get an Identity Protection PIN (IP PIN)
- File Your Taxes for Free
- Bank Account (Direct Pay)
- Payment Plan (Installment Agreement)
- Electronic Federal Tax Payment System (EFTPS)
- Your Online Account
- Tax Withholding Estimator
- Estimated Taxes
- Where's My Refund
- What to Expect
- Direct Deposit
- Reduced Refunds
- Amend Return
Credits & Deductions
- INFORMATION FOR...
- Businesses & Self-Employed
- Earned Income Credit (EITC)
- Child Tax Credit
- Clean Energy and Vehicle Credits
- Standard Deduction
- Retirement Plans
Forms & Instructions
- POPULAR FORMS & INSTRUCTIONS
- Form 1040 Instructions
- Form 4506-T
- POPULAR FOR TAX PROS
- Form 1040-X
- Circular 230
IRS enters next stage of Employee Retention Credit work; review indicates vast majority show risk of being improper
More in news.
- Topics in the news
- News releases for frequently asked questions
- Multimedia center
- Tax relief in disaster situations
- Inflation Reduction Act
- Taxpayer First Act
- Tax scams and consumer alerts
- The tax gap
- Fact sheets
- IRS Tax Tips
- e-News subscriptions
- IRS guidance
- Media contacts
- IRS statements and announcements
Highest-risk claims being denied, additional processing to begin on low-risk claims; heightened scrutiny and review continues as compliance work tops $2 billion; IRS will consult with Congress on potential legislative action before making decision on future of moratorium
IR-2024-169, June 20, 2024
WASHINGTON — Following a detailed review to protect taxpayers and small businesses, the Internal Revenue Service today announced plans to deny tens of thousands of improper high-risk Employee Retention Credit claims while starting a new round of processing lower-risk claims to help eligible taxpayers.
“The completion of this review provided the IRS with new insight into risky Employee Retention Credit activity and confirmed widespread concerns about a large number of improper claims,” said IRS Commissioner Danny Werfel. “We will now use this information to deny billions of dollars in clearly improper claims and begin additional work to issue payments to help taxpayers without any red flags on their claims.”
“This is one of the most complex credits the IRS has administered, and we continue to ask taxpayers for patience as we unravel this complex process,” Werfel added. “Ultimately, this period will help us protect taxpayers against improper payouts that flooded the system and get checks to those truly eligible.”
The review involved months of digitizing information and analyzing data since last September to assess a group of more than 1 million Employee Retention Credit (ERC) claims representing more than $86 billion filed amid aggressive marketing last year.
During this process, the IRS identified between 10% and 20% of claims fall into what the agency has determined to be the highest-risk group, which show clear signs of being erroneous claims for the pandemic-era credit. Tens of thousands of these will be denied in the weeks ahead. This high-risk group includes filings with warning signals that clearly fall outside the guidelines established by Congress.
In addition to this highest risk group, the IRS analysis also estimates between 60% and 70% of the claims show an unacceptable level of risk. For this category of claims with risk indicators, the IRS will be conducting additional analysis to gather more information with a goal of improving the agency’s compliance review, speeding resolution of valid claims while protecting against improper payments.
At the same time, the IRS continues to be concerned about small businesses waiting on legitimate claims, and the agency is taking more action to help. Between 10% and 20% of the ERC claims show a low risk. For those with no eligibility warning signs that were received prior to the last fall’s moratorium, the IRS will begin judiciously processing more of these claims.
The IRS anticipates some of the first payments in this group will go out later this summer. But the IRS emphasized these will go out at a dramatically slower pace than payments that went out during the pandemic period given the need for increased scrutiny.
As the additional IRS processing work begins at a measured pace, other claims will begin being paid later this summer following a final review. This additional review is needed because the submissions may have calculation errors made during the complex filings. For those claims with calculation errors, the amount claimed will be adjusted before payment.
The IRS also noted that generally the oldest claims will be worked first, and no claims submitted during the moratorium period will be processed at this time.
No additional action needed by taxpayers at this time; await further notification from the IRS
The IRS cautioned taxpayers who filed ERC claims that the process will take time, and the agency warned that processing speeds will not return to levels that occurred last summer. Taxpayers with claims do not need to take any action at this point, and they should await further notification from the IRS. The agency emphasized those with ERC claims should not call IRS toll-free lines because additional information is generally not available on these claims as processing work continues.
“These complex claims take time, and the IRS remains deeply concerned about how many taxpayers have been misled and deluded by promoters into thinking they’re eligible for a big payday. The reality is many aren’t,” Werfel said. “People may think they are on safe ground, but many are simply not eligible under the law. The IRS continues to urge those with pending claims to use this period to review the guideline checklist on IRS.gov, talk to a legitimate tax professional rather than a promoter and use the special IRS withdrawal program when there’s an issue.”
Werfel also cautioned taxpayers to be wary of promoters using today’s announcement as a springboard to attract more clients to file ERC claims.
“The whole world has changed involving Employee Retention Credits since the deepest days of the pandemic,” Werfel said. “Anyone applying for this credit needs to talk to a trusted tax professional and closely review the eligibility requirements, not someone playing fast and loose and trying to make a fast buck off well-meaning taxpayers. People need to be cautious of promoters trying to take advantage of today’s announcement to drive more business. People should remember the IRS continues to be very active in our compliance lanes on Employee Retention Credits.”
Steps taken since September 2023 when processing moratorium on new ERC claims began
During the ERC review period, the IRS continued to process claims received prior to September 2023. The agency processed 28,000 claims worth $2.2 billion and disallowed more than 14,000 claims worth more than $1 billion.
The ERC program began as a critical effort to help businesses during the pandemic, but the program later became the target of aggressive marketing well after the pandemic ended. Some promoter groups may have called the credit by another name, such as a grant, business stimulus payment, government relief or other names besides ERC or the Employee Retention Tax Credit (ERTC).
To counter the flood of claims being driven by promoters, the IRS announced last fall a moratorium on processing claims submitted after Sept. 14, 2023, to give the agency time to digitize information on the large study group of nearly 1 million ERC claims, which are made on amended paper tax returns. The subsequent analysis of the results during this period helped the IRS evaluate next steps, providing the IRS valuable information to change the way the agency will process ERC claims going forward.
The findings of the IRS review confirmed concerns raised by tax professionals and others that there was an extremely high rate of improper ERC claims.
The claims followed a flurry of aggressive marketing and promotions last year that led to people being misled into filing for the ERC. After the moratorium was put in place on Sept. 14, the IRS has continued to see ERC claims continuing to come in at the rate of more than 17,000 a week, with the ERC inventory currently at 1.4 million.
In light of the large inventory and the results of the ERC review, the IRS will keep the processing moratorium in place on ERC claims submitted after Sept. 14, 2023. The IRS will use this period to gather additional feedback from partners, including Congress and others, on the future course of ERC.
“We decided to keep the post-September moratorium in place because we continue to be concerned about the substantial number of claims coming in so long after the pandemic,” Werfel said. “These claims are clogging the system for legitimate taxpayers. We worry that ending the moratorium might trigger a gold rush by aggressive marketers that could lead to a new round of improper claims, which would be a bad result for taxpayers or tax administration. We will use this time to consult with Congress and seek additional help from them on the ERC program, including potentially closing down new claims entirely and seeking an extension of the statute of limitations to allow the agency more time to pursue improper claims.”
Special IRS Withdrawal Program remains open for those with unprocessed ERC claims
Given the large number of questionable claims indicated by the new review, the IRS continues to urge those with unprocessed claims to consider the special IRS ERC Withdrawal Program to avoid future compliance issues.
Businesses should quickly pursue the claim withdrawal process if they need to ask the IRS to not process an ERC claim for any tax period that hasn’t been paid yet. Taxpayers who received an ERC check — but haven’t cashed or deposited it — can also use this process to withdraw the claim and return the check. The IRS will treat the claim as though the taxpayer never filed it. No interest or penalties will apply.
With more than 1.4 million unprocessed ERC claims, the claim withdrawal process remains an important option for businesses who may have submitted an improper claim.
IRS compliance work tops $2 billion from Voluntary Disclosure Program, withdrawal process, disallowances
The IRS also announced today that compliance efforts around erroneous ERC claims have now topped more than $2 billion since last fall. This is nearly double the amount announced in March following completion of the special ERC Voluntary Disclosure Program (VDP), which the IRS announced led to the disclosure of $1.09 billion from over 2,600 applications. The IRS is currently considering reopening the VDP at a reduced rate for those with previously processed claims to avoid future compliance action by the IRS.
Compliance work on previously processed ERC claims continue, and work continues on a number of efforts to counter questionable claims:
- The ongoing claim withdrawal process for those with unprocessed ERC claims has led to more than 4,800 entities withdrawing $531 million.
- The IRS has determined that more than 12,000 entities filed over 22,000 claims that were improper and resulted in $572 million in assessments. This initial round of letters covers Tax Year 2020. Thousands more of these letters are planned in coming months to address Tax Year 2021, which involved larger claims. Congress increased the maximum ERC from $5,000 per employee per year in 2020, to $7,000 per employee for each quarter of the year in 2021.
- More than 2,600 applications for the special ERC Voluntary Disclosure Program (VDP) , which ended in March, disclosed $1.09 billion.
The IRS is currently assessing whether to reopen the special ERC Voluntary Disclosure Program to help taxpayers get into compliance on paid claims and avoid future IRS compliance action, including audits. If the program reopens, the IRS anticipates the terms will not be as favorable as the initial offering that closed in the spring. A decision will be made in coming weeks.
The IRS also reminded those with pending claims or considering submitting an ERC claim about other compliance actions underway:
Criminal investigations: As of May 31, 2024, IRS Criminal Investigation has initiated 450 criminal cases, with potentially fraudulent claims worth nearly $7 billion. In all, 36 investigations have resulted in federal charges so far, with 16 investigations resulting in convictions and seven sentencings with an average sentence of 25 months.
Audits: The IRS has thousands of ERC claims currently under audit.
Promoter investigations: The IRS is gathering information about suspected abusive tax promoters and preparers improperly promoting the ability to claim the ERC. The IRS’s Office of Promoter Investigations has received hundreds of referrals from internal and external sources. The IRS will continue civil and criminal enforcement efforts of these unscrupulous promoters and preparers.
Help for businesses with eligibility questions and those misled by promoters
Some promoters told taxpayers every employer qualifies for ERC. The IRS and the tax professional community emphasize that this is not true. Eligibility depends on specific facts and circumstances. The IRS has dozens of resources to help people learn about and check ERC eligibility and businesses can also consult their trusted tax professional . Key IRS materials to help show taxpayers if they have a risky ERC claim include:
- ERC Eligibility Checklist (interactive version and a printable guide PDF ) includes cautions about common areas of misinformation and links to facts and examples.
- 7 warning signs ERC claims may be incorrect outlines tactics that unscrupulous promoters have used and why their points are wrong.
- Frequently asked questions about the Employee Retention Credit includes eligibility rules, definitions, examples and more.
- Facebook
- Twitter
- Linkedin
Information
Initiatives
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess .
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
- Active Journals
- Find a Journal
- Proceedings Series
- For Authors
- For Reviewers
- For Editors
- For Librarians
- For Publishers
- For Societies
- For Conference Organizers
- Open Access Policy
- Institutional Open Access Program
- Special Issues Guidelines
- Editorial Process
- Research and Publication Ethics
- Article Processing Charges
- Testimonials
- Preprints.org
- SciProfiles
- Encyclopedia
![Cancers cancers-logo](https://pub.mdpi-res.com/img/journals/cancers-logo.png?8600e93ff98dbf14)
Article Menu
![stages in literature review process stages in literature review process](https://www.mdpi.com/bundles/mdpisciprofileslink/img/unknown-user.png)
- Subscribe SciFeed
- Recommended Articles
- Author Biographies
- Google Scholar
- on Google Scholar
- Table of Contents
Find support for a specific problem in the support section of our website.
Please let us know what you think of our products and services.
Visit our dedicated information section to learn more about MDPI.
JSmol Viewer
Discovering potential in non-cancer medications: a promising breakthrough for multiple myeloma patients.
![stages in literature review process stages in literature review process](https://www.mdpi.com/profiles/1641011/thumb/Omar_S._Al-Odat.jpeg)
Simple Summary
1. the significance of repurposing, 2. pharmacological repurposing strategies and tools, 3. medicines that could be repurposed to treat mm, 3.1. thalidomide, 3.2. statins, 3.3. celecoxib, 3.4. aspirin, 3.5. clarithromycin, 3.6. rapamycin, 3.7. valproic acid, 3.8. nelfinavir, 3.9. metformin, 3.10. bisphosphonates, 3.12. albendazole, 4. conclusions and future prospectives, 5. practice points.
- Although there have been numerous clinical trials conducted to evaluate different approaches for treating cancer, the 5-year survival rate for individuals with MM in the US remains at a modest 55%.
- Myeloma remains a challenging malignancy to treat due to the development of drug resistance, resulting in relapse for all patients.
- There is an ongoing demand for new medications. However, the process of finding a new treatment can often be quite time-consuming. Therefore, repurposing already approved non-cancer medication for MM can aid in the discovery of new effective drugs.
- The potential for repurposing approved drugs is promising, although a thorough analysis of these agents is necessary before they can be considered for clinical trials.
6. Research Agenda
- The potential of various non-anti-cancer drugs as an anti-myeloma treatment was discussed.
- Thalidomide stands out as an exemplary repurposed agent for treating MM.
- There is encouraging evidence that statins, rapamycin, clarithromycin, and leflunomide can inhibit MM.
- Extensive animal studies using the MM animal model, along with phase 1 clinical studies, are necessary to thoroughly investigate these agents as potential MM therapies.
Author Contributions
Conflicts of interest.
- Yang, J.; Liu, X.; Zhong, Q.-Z.; Yang, Y.; Wu, T.; Chen, S.-Y.; Chen, B.; Song, Y.-W.; Fang, H.; Wang, S.-L.; et al. Disparities in mortality risk after diagnosis of hematological malignancies in 185 countries: A global data analysis. Cancer Lett. 2024 , 595 , 216793. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Ashburn, T.T.; Thor, K.B. Drug repositioning: Identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 2004 , 3 , 673–683. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Scannell, J.W.; Blanckley, A.; Boldon, H.; Warrington, B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 2012 , 11 , 191–200. [ Google Scholar ] [ PubMed ]
- Pammolli, F.; Magazzini, L.; Riccaboni, M. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 2011 , 10 , 428–438. [ Google Scholar ] [ PubMed ]
- Waring, M.J.; Arrowsmith, J.; Leach, A.R.; Leeson, P.D.; Mandrell, S.; Owen, R.M.; Pairaudeau, G.; Pennie, W.D.; Pickett, S.D.; Wang, J.; et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 2015 , 14 , 475–486. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Beachy, S.H.; Johnson, S.G.; Olson, S.; Berger, A.C. Drug Repurposing and Repositioning: Workshop Summary ; National Academies Press: Washington, DC, USA, 2014. [ Google Scholar ]
- DiMasi, J.A.; Grabowski, H.G.; Hansen, R.W. Innovation in the pharmaceutical industry: New estimates of R&D costs. J. Health Econ. 2016 , 47 , 20–33. [ Google Scholar ] [ PubMed ]
- Paul, S.M.; Mytelka, D.S.; Dunwiddie, C.T.; Persinger, C.C.; Munos, B.H.; Lindborg, S.R.; Schacht, A.L. How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nat. Rev. Drug Discov. 2010 , 9 , 203–214. [ Google Scholar ] [ PubMed ]
- Papapetropoulos, A.; Szabo, C. Inventing new therapies without reinventing the wheel: The power of drug repurposing. Br. J. Pharmacol. 2018 , 175 , 165–167. [ Google Scholar ] [ CrossRef ]
- Hernandez, J.J.; Pryszlak, M.; Smith, L.; Yanchus, C.; Kurji, N.; Shahani, V.M.; Molinski, S.V. Giving drugs a second chance: Overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front. Oncol. 2017 , 7 , 273. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Nosengo, N. Can you teach old drugs new tricks? Nature 2016 , 534 , 314–316. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Ishida, J.; Konishi, M.; Ebner, N.; Springer, J. Repurposing of approved cardiovascular drugs. J. Transl. Med. 2016 , 14 , 269. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Cheng, F.; Lu, W.; Liu, C.; Fang, J.; Hou, Y.; Handy, D.E.; Wang, R.; Zhao, Y.; Yang, Y.; Huang, J.; et al. A genome-wide positioning systems network algorithm for in silico drug repurposing. Nat. Commun. 2019 , 10 , 3476. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Rudrapal, M.; Khairnar, S.J.; Jadhav, A.G. Drug repurposing (DR): An emerging approach in drug discovery. In Drug Repurposing-Hypothesis, Molecular Aspects and Therapeutic Applications ; IntechOpe: London, UK, 2020; Volume 10. [ Google Scholar ]
- Rajkumar, S.V.; Kumar, S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020 , 10 , 94. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Dehghanifard, A.; Kaviani, S.; Abroun, S.; Mehdizadeh, M.; Saiedi, S.; Maali, A.; Ghaffari, S.; Azad, M. Various signaling pathways in multiple myeloma cells and effects of treatment on these pathways. Clin. Lymphoma Myeloma Leuk. 2018 , 18 , 311–320. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Al-Odat, O.S.; von Suskil, M.; Chitren, R.J.; Elbezanti, W.O.; Srivastava, S.K.; Budak-Alpddogan, T.; Jonnalagadda, S.C.; Aggarwal, B.B.; Pandey, M. Mcl-1 inhibition: Managing malignancy in multiple myeloma. Front. Pharmacol. 2021 , 12 , 699629. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Hurle, M.R.; Yang, L.; Xie, Q.; Rajpal, D.K.; Sanseau, P.; Agarwal, P. Computational drug repositioning: From data to therapeutics. Clin. Pharmacol. Ther. 2013 , 93 , 335–341. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Keiser, M.J.; Setola, V.; Irwin, J.J.; Laggner, C.; Abbas, A.I.; Hufeisen, S.J.; Jensen, N.H.; Kuijer, M.B.; Matos, R.C.; Tran, T.B.; et al. Predicting new molecular targets for known drugs. Nature 2009 , 462 , 175–181. [ Google Scholar ] [ CrossRef ]
- Hieronymus, H.; Lamb, J.; Ross, K.N.; Peng, X.P.; Clement, C.; Rodina, A.; Nieto, M.; Du, J.; Stegmaier, K.; Raj, S.M.; et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006 , 10 , 321–330. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Cheng, F.; Desai, R.J.; Handy, D.E.; Wang, R.; Schneeweiss, S.; Barabási, A.L.; Loscalzo, J. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat. Commun. 2018 , 9 , 2691. [ Google Scholar ] [ CrossRef ]
- Nam, Y.; Kim, M.; Chang, H.S.; Shin, H. Drug repurposing with network reinforcement. BMC Bioinform. 2019 , 20 , 383. [ Google Scholar ] [ CrossRef ]
- Zickenrott, S.; Angarica, V.E.; Upadhyaya, B.B.; Del Sol, A. Prediction of disease–gene–drug relationships following a differential network analysis. Cell Death Dis. 2016 , 7 , e2040. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Hu, G.; Agarwal, P. Human disease-drug network based on genomic expression profiles. PLoS ONE 2009 , 4 , e6536. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Peyvandipour, A.; Saberian, N.; Shafi, A.; Donato, M.; Draghici, S. A novel computational approach for drug repurposing using systems biology. Bioinformatics 2018 , 34 , 2817–2825. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Naylor, D.M.; Kauppi, D.; Schonfeld, J. Therapeutic drug repurposing, repositioning and rescue. Drug Discov. 2015 , 57 , 1–16. [ Google Scholar ]
- Chatr-Aryamontri, A.; Breitkreutz, B.-J.; Heinicke, S.; Boucher, L.; Winter, A.; Stark, C.; Nixon, J.; Ramage, L.; Kolas, N.; O’Donnell, L.; et al. The BioGRID interaction database: 2013 update. Nucleic Acids Res. 2012 , 41 , D816–D823. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Szklarczyk, D.; Franceschini, A.; Wyder, S.; Forslund, K.; Heller, D.; Huerta-Cepas, J.; Simonovic, M.; Roth, A.; Santos, A.; Tsafou, K.P. STRING v10: Protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015 , 43 , D447–D452. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Chen, J.Y.; Pandey, R.; Nguyen, T.M. HAPPI-2: A comprehensive and high-quality map of human annotated and predicted protein interactions. BMC Genom. 2017 , 18 , 182. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Kanehisa, M.; Furumichi, M.; Tanabe, M.; Sato, Y.; Morishima, K. KEGG: New perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 , 45 , D353–D361. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Croft, D.; O’Kelly, G.; Wu, G.; Haw, R.; Gillespie, M.; Matthews, L.; Caudy, M.; Garapati, P.; Gopinath, G.; Jassal, B.; et al. Reactome: A database of reactions, pathways and biological processes. Nucleic Acids Res. 2011 , 39 , D691–D697. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Wang, Z.; Jensen, M.; Zenklusen, J. A Practical Guide to the Cancer Genome Atlas (TCGA). Statistical Genomics. Methods Protoc. 2016 , 1418 , 111–141. [ Google Scholar ]
- Uhlén, M.; Fagerberg, L.; Hallström, B.M.; Lindskog, C.; Oksvold, P.; Mardinoglu, A.; Sivertsson, Å.; Kampf, C.; Sjöstedt, E.; Asplund, A.; et al. Tissue-based map of the human proteome. Science 2015 , 347 , 1260419. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Uhlen, M.; Oksvold, P.; Fagerberg, L.; Lundberg, E.; Jonasson, K.; Forsberg, M.; Zwahlen, M.; Kampf, C.; Wester, K.; Hober, S.; et al. Towards a knowledge-based human protein atlas. Nat. Biotechnol. 2010 , 28 , 1248–1250. [ Google Scholar ] [ CrossRef ]
- Uhlén, M.; Björling, E.; Agaton, C.; Szigyarto, C.A.-K.; Amini, B.; Andersen, E.; Andersson, A.-C.; Angelidou, P.; Asplund, A.; Asplund, C.; et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol. Cell. Proteom. 2005 , 4 , 1920–1932. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Barretina, J.; Caponigro, G.; Stransky, N.; Venkatesan, K.; Margolin, A.A.; Kim, S.; Wilson, C.J.; Lehár, J.; Kryukov, G.V.; Sonkin, D.; et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012 , 483 , 603–607. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Lamb, J.; Crawford, E.D.; Peck, D.; Modell, J.W.; Blat, I.C.; Wrobel, M.J.; Lerner, J.; Brunet, J.-P.; Subramanian, A.; Ross, K.N.; et al. The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 2006 , 313 , 1929–1935. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Lamb, J. The Connectivity Map: A new tool for biomedical research. Nat. Rev. Cancer 2007 , 7 , 54–60. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Borate, B.; Baxevanis, A.D. Searching Online Mendelian Inheritance in Man (OMIM) for information on genetic loci involved in human disease. Curr. Protoc. Bioinform. 2009 , 27 , 1.2.1–1.2.13. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Goh, K.-I.; Cusick, M.E.; Valle, D.; Childs, B.; Vidal, M.; Barabási, A.-L. The human disease network. Proc. Natl. Acad. Sci. USA 2007 , 104 , 8685–8690. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Yang, J.; Wu, S.-J.; Yang, S.-Y.; Peng, J.-W.; Wang, S.-N.; Wang, F.-Y.; Song, Y.-X.; Qi, T.; Li, Y.-X.; Li, Y.-Y. DNetDB: The human disease network database based on dysfunctional regulation mechanism. BMC Syst. Biol. 2016 , 10 , 36. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Law, V.; Knox, C.; Djoumbou, Y.; Jewison, T.; Guo, A.C.; Liu, Y.; Maciejewski, A.; Arndt, D.; Wilson, M.; Neveu, V.; et al. DrugBank 4.0: Shedding new light on drug metabolism. Nucleic Acids Res. 2014 , 42 , D1091–D1097. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Andersson, M.L.; Böttiger, Y.; Bastholm-Rahmner, P.; Ovesjö, M.-L.; Veg, A.; Eiermann, B. Evaluation of usage patterns and user perception of the drug–drug interaction database SFINX. Int. J. Med. Inform. 2015 , 84 , 327–333. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Kale, V.P.; Habib, H.; Chitren, R.; Patel, M.; Pramanik, K.C.; Jonnalagadda, S.C.; Challagundla, K.; Pandey, M.K. Old drugs, new uses: Drug repurposing in hematological malignancies. Semin. Cancer Biol. 2021 , 68 , 242–248. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Kuhn, M.; Letunic, I.; Jensen, L.J.; Bork, P. The SIDER database of drugs and side effects. Nucleic Acids Res. 2016 , 44 , D1075–D1079. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Siramshetty, V.B.; Nickel, J.; Omieczynski, C.; Gohlke, B.-O.; Drwal, M.N.; Preissner, R. WITHDRAWN—A resource for withdrawn and discontinued drugs. Nucleic Acids Res. 2016 , 44 , D1080–D1086. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Kuhn, M.; Szklarczyk, D.; Franceschini, A.; Von Mering, C.; Jensen, L.J.; Bork, P. STITCH 3: Zooming in on protein–chemical interactions. Nucleic Acids Res. 2012 , 40 , D876–D880. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Shameer, K.; Glicksberg, B.S.; Hodos, R.; Johnson, K.W.; Badgeley, M.A.; Readhead, B.; Tomlinson, M.S.; O’Connor, T.; Miotto, R.; Kidd, B.A.; et al. Systematic analyses of drugs and disease indications in RepurposeDB reveal pharmacological, biological and epidemiological factors influencing drug repositioning. Brief. Bioinform. 2018 , 19 , 656–678. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Garnett, M.J.; Edelman, E.J.; Heidorn, S.J.; Greenman, C.D.; Dastur, A.; Lau, K.W.; Greninger, P.; Thompson, I.R.; Luo, X.; Soares, J.; et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012 , 483 , 570–575. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Lee, B.K.B.; Tiong, K.H.; Chang, J.K.; Liew, C.S.; Abdul Rahman, Z.A.; Tan, A.C.; Khang, T.F.; Cheong, S.C. DeSigN: Connecting gene expression with therapeutics for drug repurposing and development. BMC Genom. 2017 , 18 , 934. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Singhal, S.; Mehta, J.; Desikan, R.; Ayers, D.; Roberson, P.; Eddlemon, P.; Munshi, N.; Anaissie, E.; Wilson, C.; Dhodapkar, M.; et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 1999 , 341 , 1565–1571. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Rajkumar, S.V.; Blood, E.; Vesole, D.; Fonseca, R.; Greipp, P.R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol. 2006 , 24 , 431–436. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Afzal, A.; Fiala, M.A.; Gage, B.F.; Wildes, T.M.; Sanfilippo, K. Statins reduce mortality in multiple myeloma: A population-based US study. Clin. Lymphoma Myeloma Leuk. 2020 , 20 , e937–e943. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Brånvall, E.; Ekberg, S.; Eloranta, S.; Wästerlid, T.; Birmann, B.M.; Smedby, K.E. Statin use is associated with improved survival in multiple myeloma: A Swedish population-based study of 4315 patients. Am. J. Hematol. 2020 , 95 , 652–661. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Sanfilippo, K.M.; Keller, J.; Gage, B.F.; Luo, S.; Wang, T.-F.; Moskowitz, G.; Gumbel, J.; Blue, B.; O’Brian, K.; Carson, K.R. Statins are associated with reduced mortality in multiple myeloma. J. Clin. Oncol. 2016 , 34 , 4008–4014. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Epstein, M.M.; Divine, G.; Chao, C.R.; Wells, K.E.; Feigelson, H.S.; Scholes, D.; Roblin, D.; Ulcickas Yood, M.; Engel, L.S.; Taylor, A.; et al. Statin use and risk of multiple myeloma: An analysis from the cancer research network. Int. J. Cancer 2017 , 141 , 480–487. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Bernard, M.; Bancos, S.; Sime, P.; Phipps, R. Targeting cyclooxygenase-2 in hematological malignancies: Rationale and promise. Curr. Pharm. Des. 2008 , 14 , 2051–2060. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Tołoczko-Iwaniuk, N.; Dziemiańczyk-Pakieła, D.; Nowaszewska, B.K.; Celińska-Janowicz, K.; Miltyk, W. Celecoxib in cancer therapy and prevention—Review. Curr. Drug Targets 2019 , 20 , 302–315. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Kardosh, A.; Soriano, N.; Liu, Y.-T.; Uddin, J.; Petasis, N.A.; Hofman, F.M.; Chen, T.C.; Schönthal, A.H. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non–COX-2 inhibitory analog of celecoxib. Blood 2005 , 106 , 4330–4338. [ Google Scholar ] [ CrossRef ]
- Marinac, C.R.; Colditz, G.A.; Rosner, B.; Ghobrial, I.M.; Birmann, B.M. Aspirin Use and Survival in Multiple Myeloma Patients. Blood 2018 , 132 , 3250. [ Google Scholar ] [ CrossRef ]
- Birmann, B.M.; Giovannucci, E.L.; Rosner, B.A.; Colditz, G.A. Regular aspirin use and risk of multiple myeloma: A prospective analysis in the health professionals follow-up study and nurses’ health study. Cancer Prev. Res. 2014 , 7 , 33–41. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Holien, T.; Olsen, O.E.; Misund, K.; Hella, H.; Waage, A.; Rø, T.B.; Sundan, A. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate. Eur. J. Haematol. 2013 , 91 , 339–346. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Papanikolaou, X.; Johnson, S.; Garg, T.; Tian, E.; Tytarenko, R.; Zhang, Q.; Stein, C.; Barlogie, B.; Epstein, J.; Heuck, C. Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis. Oncotarget 2014 , 5 , 4118–4128. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Li, S.; Xue, F.; Cheng, Z.; Yang, X.; Wang, S.; Geng, F.; Pan, L. Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFκB p65. Int. J. Hematol. 2009 , 90 , 513–521. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Hu, G.-F.; Dong, K.; Dong, J.-F.; Wang, Y.; Gao, W. Effects of Artesunate Combined with Arsenious Acid on Proliferation and Apoptosis of Multiple Myeloma Cells via PI3K/AKT Signaling Pathway. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 , 29 , 1819–1824. [ Google Scholar ] [ PubMed ]
- Baumann, P.; Mandl-Weber, S.; Volkl, A.; Adam, C.; Bumeder, I.; Oduncu, F.; Schmidmaier, R. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol. Cancer Ther. 2009 , 8 , 366–375. [ Google Scholar ] [ CrossRef ]
- Rosenzweig, M.; Palmer, J.; Tsai, N.-C.; Synold, T.; Wu, X.; Tao, S.; Hammond, S.N.; Buettner, R.; Duarte, L.; Htut, M.; et al. Repurposing leflunomide for relapsed/refractory multiple myeloma: A phase 1 study. Leuk. Lymphoma 2020 , 61 , 1669–1677. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Van Nuffel, A.M.; Sukhatme, V.; Pantziarka, P.; Meheus, L.; Sukhatme, V.P.; Bouche, G. Repurposing Drugs in Oncology (ReDO)—Clarithromycin as an anti-cancer agent. Ecancermedicalscience 2015 , 9 , 513. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Mark, T.M.; Bowman, I.A.; Rossi, A.C.; Shah, M.; Rodriguez, M.; Quinn, R.; Pearse, R.N.; Zafar, F.; Pekle, K.; Jayabalan, D.; et al. Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. Leuk. Lymphoma 2014 , 55 , 2842–2849. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Strömberg, T.; Dimberg, A.; Hammarberg, A.; Carlson, K.; Osterborg, A.; Nilsson, K.; Jernberg-Wiklund, H. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 2004 , 103 , 3138–3147. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Gera, J.; Lichtenstein, A. The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma. Leuk. Lymphoma 2011 , 52 , 1857–1866. [ Google Scholar ] [ CrossRef ]
- Raje, N.; Kumar, S.; Hideshima, T.; Ishitsuka, K.; Chauhan, D.; Mitsiades, C.; Podar, K.; Le Gouill, S.; Richardson, P.; Munshi, N.C.; et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004 , 104 , 4188–4193. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Yee, A.J.; Hari, P.; Marcheselli, R.; Mahindra, A.K.; Cirstea, D.D.; Scullen, T.A.; Burke, J.N.; Rodig, S.J.; Hideshima, T.; Laubach, J.P.; et al. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br. J. Haematol. 2014 , 166 , 401–409. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Kikuchi, J.; Wada, T.; Shimizu, R.; Izumi, T.; Akutsu, M.; Mitsunaga, K.; Noborio-Hatano, K.; Nobuyoshi, M.; Ozawa, K.; Kano, Y.; et al. Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood J. Am. Soc. Hematol. 2010 , 116 , 406–417. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Bono, C.; Karlin, L.; Harel, S.; Mouly, E.; Labaume, S.; Galicier, L.; Apcher, S.; Sauvageon, H.; Fermand, J.-P.; Bories, J.-C.; et al. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica 2012 , 97 , 1101–1109. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Kraus, M.; Bader, J.; Overkleeft, H.; Driessen, C. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. Blood Cancer J. 2013 , 3 , e103. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Alodhaibi, I.; Ailawadhi, S.; Burbano, G.P.; O’Brien, P.J.; Buadi, F.K.; Hayman, S.; Kumar, S.K.; Gonsalves, W.I. An Open-Label Phase I Study of Metformin and Nelfinavir in Combination with Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Clin. Lymphoma Myeloma Leuk. 2024 , 24 , 298–304. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Koltai, T. Nelfinavir and other protease inhibitors in cancer: Mechanisms involved in anticancer activity. F1000Research 2015 , 4 , 9. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Dalva-Aydemir, S.; Bajpai, R.; Martinez, M.; Adekola, K.U.; Kandela, I.; Wei, C.; Singhal, S.; Koblinski, J.E.; Raje, N.S.; Rosen, S.T.; et al. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. Clin. Cancer Res. 2015 , 21 , 1161–1171. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Mishra, R.K.; Wei, C.; Hresko, R.C.; Bajpai, R.; Heitmeier, M.; Matulis, S.M.; Nooka, A.K.; Rosen, S.T.; Hruz, P.W.; Schiltz, G.E.; et al. In silico modeling-based identification of glucose transporter 4 (GLUT4)-selective inhibitors for cancer therapy. J. Biol. Chem. 2015 , 290 , 14441–14453. [ Google Scholar ] [ CrossRef ]
- Jagannathan, S.; Abdel-Malek, M.; Malek, E.; Vad, N.; Latif, T.; Anderson, K.; Driscoll, J. Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib. Leukemia 2015 , 29 , 2184–2191. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Mansour, A.; Wakkach, A.; Blin-Wakkach, C. Emerging roles of osteoclasts in the modulation of bone microenvironment and immune suppression in multiple myeloma. Front. Immunol. 2017 , 8 , 954. [ Google Scholar ] [ CrossRef ]
- Tai, Y.-T.; Cho, S.-F.; Anderson, K.C. Osteoclast immunosuppressive effects in multiple myeloma: Role of programmed cell death ligand 1. Front. Immunol. 2018 , 9 , 1822. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Chroma, K.; Skrott, Z.; Gursky, J.; Bacovsky, J.; Moudry, P.; Buchtova, T.; Mistrik, M.; Bartek, J. A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment. Cell Death Dis. 2022 , 13 , 203. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Yi, H.; Liang, L.; Wang, H.; Luo, S.; Hu, L.; Wang, Y.; Shen, X.; Xiao, L.; Zhang, Y.; Peng, H.; et al. Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma. Cancer Lett. 2021 , 520 , 307–320. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Kumar, S.; Witzig, T.; Rajkumar, S.V. Thalidomide as an anti-cancer agent. J. Cell. Mol. Med. 2002 , 6 , 160–174. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Miller, M.T. Thalidomide embryopathy: A model for the study of congenital incomitant horizontal strabismus. Trans. Am. Ophthalmol. Soc. 1991 , 89 , 623–674. [ Google Scholar ] [ PubMed ]
- Grover, J.; Vats, V.; Gopalakrishna, R.; Ramam, M. Thalidomide: A re-look. Natl. Med. J. India 2000 , 13 , 132–141. [ Google Scholar ] [ PubMed ]
- Perri, A.J., III; Hsu, S. A review of thalidomide’s history and current dermatological applications. Dermatol. Online J. 2003 , 9 , 5. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Gordon, J.; Goggin, P. Thalidomide and its derivatives: Emerging from the wilderness. Postgrad. Med. J. 2003 , 79 , 127–132. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Holmes, A.; McMenamin, M.; Mulcahy, F.; Bergin, C. Thalidomide Therapy for the Treatment of Hypertrophic Herpes Simplex Virus—Related Genitalis in HIV-Infected Individuals. Clin. Infect. Dis. 2007 , 44 , e96–e99. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Holland, S. Cytokine therapy of mycobacterial infections. Adv. Intern. Med. 2000 , 45 , 431–452. [ Google Scholar ] [ PubMed ]
- Gupta, S.C.; Sung, B.; Prasad, S.; Webb, L.J.; Aggarwal, B.B. Cancer drug discovery by repurposing: Teaching new tricks to old dogs. Trends Pharmacol. Sci. 2013 , 34 , 508–517. [ Google Scholar ] [ CrossRef ]
- Locksley, R.M.; Killeen, N.; Lenardo, M.J. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001 , 104 , 487–501. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Hideshima, T.; Chauhan, D.; Richardson, P.; Mitsiades, C.; Mitsiades, N.; Hayashi, T.; Munshi, N.; Dang, L.; Castro, A.; Palombella, V.; et al. NF-κB as a therapeutic target in multiple myeloma. J. Biol. Chem. 2002 , 277 , 16639–16647. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Singhal, S.; Mehta, J. Thalidomide in cancer. Biomed. Pharmacother. 2002 , 56 , 4–12. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Kumar, V.; Chhibber, S. Thalidomide: An old drug with new action. J. Chemother. 2011 , 23 , 326–334. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Solèr, R.A.; Howard, M.; Brink, N.S.; Gibb, D.; Tedder, R.S.; Nadal, D. Regression of AIDS-related Kaposi’s sarcoma during therapy with thalidomide. Clin. Infect. Dis. 1996 , 23 , 501–503. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Tunio, M.A.; Hashmi, A.; Qayyum, A.; Naimatullah, N.; Masood, R. Low-dose thalidomide in patients with metastatic renal cell carcinoma. Brain 2012 , 3 , 3.75. [ Google Scholar ]
- Franks, M.E.; Macpherson, G.R.; Figg, W.D. Thalidomide. Lancet 2004 , 363 , 1802–1811. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Figg, W.D.; Hussain, M.H.; Gulley, J.L.; Arlen, P.M.; Aragon-Ching, J.B.; Petrylak, D.P.; Higano, C.S.; Steinberg, S.M.; Chatta, G.S.; Parnes, H.; et al. A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J. Urol. 2009 , 181 , 1104–1113. [ Google Scholar ] [ CrossRef ]
- Ghobrial, I.M.; Rajkumar, S.V. Management of thalidomide toxicity. J. Support. Oncol. 2003 , 1 , 194–205. [ Google Scholar ] [ PubMed ]
- Fadul, C.E.; Kingman, L.S.; Meyer, L.P.; Cole, B.F.; Eskey, C.J.; Rhodes, C.H.; Roberts, D.W.; Newton, H.B.; Pipas, J.M. A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J. Neuro-Oncol. 2008 , 90 , 229–235. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Penas-Prado, M.; Hess, K.R.; Fisch, M.J.; Lagrone, L.W.; Groves, M.D.; Levin, V.A.; De Groot, J.F.; Puduvalli, V.K.; Colman, H.; Volas-Redd, G.; et al. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro-Oncology 2015 , 17 , 266–273. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Chapman-Shimshoni, D.; Yuklea, M.; Radnay, J.; Shapiro, H.; Lishner, M. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp. Hematol. 2003 , 31 , 779–783. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Pradelli, D.; Soranna, D.; Zambon, A.; Catapano, A.; Mancia, G.; La Vecchia, C.; Corrao, G. Statins use and the risk of all and subtype hematological malignancies: A meta-analysis of observational studies. Cancer Med. 2015 , 4 , 770–780. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Yi, X.; Jia, W.; Jin, Y.; Zhen, S. Statin use is associated with reduced risk of haematological malignancies: Evidence from a meta-analysis. PLoS ONE 2014 , 9 , e87019. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Zhang, P.; Liu, B. Statin use and the risk of multiple myeloma: A PRISMA-compliant meta-analysis. Ann. Hematol. 2020 , 99 , 1805–1812. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Longo, J.; Smirnov, P.; Li, Z.; Branchard, E.; van Leeuwen, J.E.; Licht, J.D.; Haibe-Kains, B.; Andrews, D.W.; Keats, J.J.; Pugh, T.J.; et al. The mevalonate pathway is an actionable vulnerability of t (4; 14)-positive multiple myeloma. Leukemia 2021 , 35 , 796–808. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Juarez, D.; Buono, R.; Matulis, S.M.; Gupta, V.A.; Duong, M.R.; Yudiono, J.; Paul, M.; Mallya, S.; Diep, G.; Hsin, P.; et al. Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL1 inhibitors. Cancer Res. Commun. 2023 , 3 , 2497–2509. [ Google Scholar ] [ CrossRef ]
- Cetin, M.; Buyukberber, S.; Demir, M.; Sari, I.; Sari, I.; Deniz, K.; Eser, B.; Altuntas, F.; Camcı, C.; Öztürk, A.; et al. Overexpression of cyclooxygenase-2 in multiple myeloma: Association with reduced survival. Am. J. Hematol. 2005 , 80 , 169–173. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Ladetto, M.; Vallet, S.; Trojan, A.; Dell’Aquila, M.; Monitillo, L.; Rosato, R.; Santo, L.; Drandi, D.; Bertola, A.; Falco, P.; et al. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 2005 , 105 , 4784–4791. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Trojan, A.; Tinguely, M.; Vallet, S.; Seifert, B.; Jenni, B.; Zippelius, A.; Witzens-Harig, M.; Mechtersheimer, G.; Ho, A.; Goldschmidt, H.; et al. Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. Swiss Med. Wkly. 2006 , 136 , 400–403. [ Google Scholar ] [ PubMed ]
- Jendrossek, V. Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett. 2013 , 332 , 313–324. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Steinbach, G.; Lynch, P.M.; Phillips, R.K.; Wallace, M.H.; Hawk, E.; Gordon, G.B.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T.; et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000 , 342 , 1946–1952. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Scilimati, A. Patient Bone Marrow Aspiration to Explore the Cyclooxygenases (COXs) Involvement in Multiple Myeloma. J. Cancer Res. Therap. Oncol. 2021 , 9 , 1–19. [ Google Scholar ]
- Roy, P.; Sarkar, U.A.; Basak, S. The NF-κB activating pathways in multiple myeloma. Biomedicines 2018 , 6 , 59. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Fan, L.; Hong, J.; Huang, H.; Fu, D.; Wu, S.; Wang, Q.; Ye, Y.; Liu, Y. High expression of phosphorylated extracellular signal-regulated kinase (ERK1/2) is associated with poor prognosis in newly diagnosed patients with multiple myeloma. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2017 , 23 , 2636–2643. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Liu, H.; Xiong, C.; Liu, J.; Sun, T.; Ren, Z.; Li, Y.; Geng, J.; Li, X. Aspirin exerts anti-tumor effect through inhibiting Blimp1 and activating ATF4/CHOP pathway in multiple myeloma. Biomed. Pharmacother. 2020 , 125 , 110005. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Sakamoto, M.; Mikasa, K.; Hamada, K.; Konishi, M.; Maeda, K.; Yoshimoto, E.; Ueda, K.; Majima, T.; Sawaki, M.; Kita, E.; et al. Effect of clarithromycin treatment of natural killer cell activity in patients with advanced non-small cell lung cancer. Gan Kagaku Ryoho. Cancer Chemother. 1998 , 25 , 2259–2266. [ Google Scholar ] [ CrossRef ]
- Musto, P.; Falcone, A.; Sanpaolo, G.; Bodenizza, C.; Carotenuto, M.; Carella, A.M. Inefficacy of clarithromycin in advanced multiple myeloma: A definitive report. Haematologica 2002 , 87 , 658–659. [ Google Scholar ] [ PubMed ]
- Durie, B. Clarithromycin (Biaxin) as primary treatment for myeloma. Blood 1997 , 90 , 579. [ Google Scholar ]
- Stewart, A.; Trudel, S.; Al-Berouti, B.; Sutton, D.; Meharchand, J.; Shustik, C. Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma. Blood J. Am. Soc. Hematol. 1999 , 93 , 4441–4442. [ Google Scholar ]
- Moreau, P.; Huynh, A.; Facon, T.; Bouilly, I.; Sotto, J.; Legros, L.; Milpied, N.; Attal, M.; Bataille, R.; Harousseau, J.; et al. Lack of efficacy of clarithromycin in advanced multiple myeloma. Leukemia 1999 , 13 , 490–491. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Morris, T.; Ranaghan, L.; Morrison, J.; Group, N.I.R.H. Phase II trial of clarithromycin and pamidronate therapy in myeloma. Med. Oncol. 2001 , 18 , 79–84. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Coleman, M.; Leonard, J.; Lyons, L.; Pekle, K.; Nahum, K.; Pearse, R.; Niesvizky, R.; Michaeli, J. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström’s macroglobulinemia. Leuk. Lymphoma 2002 , 43 , 1777–1782. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Morris, T.; Kettle, P.; Drake, M.; Jones, F.; Hull, D.; Boyd, K.; Morrison, A.; Clarke, P.; O’Reilly, P.; Quinn, J. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. Br. J. Haematol. 2008 , 143 , 349–354. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Puig, N.; Hernández, M.T.; Rosiñol, L.; González, E.; de Arriba, F.; Oriol, A.; González-Calle, V.; Escalante, F.; de la Rubia, J.; Gironella, M.; et al. Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: A randomized trial. Blood Cancer J. 2021 , 11 , 101. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Klein, B.; Zhang, X.-G.; Lu, Z.-Y.; Bataille, R. Interleukin-6 in human multiple myeloma. Blood 1995 , 85 , 863–872. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Khan, A.; Slifer, T.; Araujo, F.; Remington, J. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int. J. Antimicrob. Agents 1999 , 11 , 121–132. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Moriya, S.; Komatsu, S.; Yamasaki, K.; Kawai, Y.; Kokuba, H.; Hirota, A.; Che, X.F.; Inazu, M.; Gotoh, A.; Hiramoto, M. Targeting the integrated networks of aggresome formation, proteasome, and autophagy potentiates ER stress-mediated cell death in multiple myeloma cells. Int. J. Oncol. 2015 , 46 , 474–486. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Takemori, N.; Ooi, H.-K.; Imai, G.; Hoshino, K.; Saio, M. Possible mechanisms of action of clarithromycin and its clinical application as a repurposing drug for treating multiple myeloma. Ecancermedicalscience 2020 , 14 , 1088. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Sehgal, S.; Baker, H.; Vézina, C. Rapamycin (AY-22, 989), a new antifungal antibiotic II. Fermentation, isolation and characterization. J. Antibiot. 1975 , 28 , 727–732. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Saunders, R.N.; Metcalfe, M.S.; Nicholson, M.L. Rapamycin in transplantation: A review of the evidence. Kidney Int. 2001 , 59 , 3–16. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Laplante, M.; Sabatini, D.M. mTOR signaling at a glance. J. Cell Sci. 2009 , 122 , 3589–3594. [ Google Scholar ] [ CrossRef ]
- Ichiyama, T.; Okada, K.; Lipton, J.M.; Matsubara, T.; Hayashi, T.; Furukawa, S. Sodium valproate inhibits production of TNF-α and IL-6 and activation of NF-κB. Brain Res. 2000 , 857 , 246–251. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Wang, Y.; Hao, C.-L.; Zhang, Z.-H.; Wang, L.-H.; Yan, L.-N.; Zhang, R.-J.; Lin, L.; Yang, Y. Valproic acid increased autophagic flux in human multiple myeloma cells in vitro. Biomed. Pharmacother. 2020 , 127 , 110167. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Zhang, Y.; Zhang, Z.; Zhao, R.; Li, H.; Wang, T.; Yan, L.; Gu, C.; Zhao, L.; Hao, C. Valproic acid activates autophagy in multiple myeloma cell lines RPMI8226 and U266. Zhonghua Xue Ye Xue Za Zhi Zhonghua Xueyexue Zazhi 2016 , 37 , 478–483. [ Google Scholar ]
- Kitazoe, K.-I.; Abe, M.; Hiasa, M.; Oda, A.; Amou, H.; Harada, T.; Nakano, A.; Takeuchi, K.; Hashimoto, T.; Ozaki, S.; et al. Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. Int. J. Hematol. 2009 , 89 , 45–57. [ Google Scholar ] [ CrossRef ]
- Yang, Y.; Ikezoe, T.; Takeuchi, T.; Adachi, Y.; Ohtsuki, Y.; Takeuchi, S.; Koeffler, H.P.; Taguchi, H. HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling. Cancer Sci. 2005 , 96 , 425–433. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Kawabata, S.; Gills, J.; Mercado-Matos, J.; Lopiccolo, J.; Wilson, W.; Hollander, M.; Dennis, P. Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. Cell Death Dis. 2012 , 3 , e353. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Kalender, A.; Selvaraj, A.; Kim, S.Y.; Gulati, P.; Brûlé, S.; Viollet, B.; Kemp, B.E.; Bardeesy, N.; Dennis, P.; Schlager, J.J.; et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010 , 11 , 390–401. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Del Barco, S.; Vazquez-Martin, A.; Cufí, S.; Oliveras-Ferraros, C.; Bosch-Barrera, J.; Joven, J.; Martin-Castillo, B.; Menendez, J.A. Metformin: Multi-faceted protection against cancer. Oncotarget 2011 , 2 , 896–917. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Greaves, D.; Calle, Y. Epithelial Mesenchymal Transition (EMT) and Associated Invasive Adhesions in Solid and Haematological Tumours. Cells 2022 , 11 , 649. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Noto, H.; Goto, A.; Tsujimoto, T.; Noda, M. Cancer risk in diabetic patients treated with metformin: A systematic review and meta-analysis. PLoS ONE 2012 , 7 , e33411. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Bodmer, M.; Meier, C.; Krähenbühl, S.; Jick, S.S.; Meier, C.R. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010 , 33 , 1304–1308. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Machado-Neto, J.A.; Fenerich, B.A.; Scopim-Ribeiro, R.; Eide, C.A.; Coelho-Silva, J.L.; Dechandt, C.R.P.; Fernandes, J.C.; Rodrigues Alves, A.P.N.; Scheucher, P.S.; Simões, B.P.; et al. Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms. Cell Death Dis. 2018 , 9 , 311. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Mishra, A.K.; Dingli, D. Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. Leukemia 2019 , 33 , 2695–2709. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Chang, S.-H.; Luo, S.; O’Brian, K.K.; Thomas, T.S.; Colditz, G.A.; Carlsson, N.P.; Carson, K.R. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: A population-based retrospective cohort study. Lancet Haematol. 2015 , 2 , e30–e36. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Boursi, B.; Mamtani, R.; Yang, Y.-X.; Weiss, B.M. Impact of metformin on the progression of MGUS to multiple myeloma. Leuk. Lymphoma 2017 , 58 , 1265–1267. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- LeGrand, J.; Park, E.S.; Wang, H.; Gupta, S.; Owens, J.D., Jr.; Nelson, P.J.; DuBois, W.; Bair, T.; Janz, S.; Mushinski, J.F. Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. Blood J. Am. Soc. Hematol. 2012 , 119 , 1018–1028. [ Google Scholar ] [ CrossRef ]
- Zhao, Y.; Zhang, E.; Lv, N.; Ma, L.; Yao, S.; Yan, M.; Zi, F.; Deng, G.; Liu, X.; He, J. Metformin and FTY720 synergistically induce apoptosis in multiple myeloma cells. Cell. Physiol. Biochem. 2018 , 48 , 785–800. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Berenson, J.R. Antitumor effects of bisphosphonates: From the laboratory to the clinic. Curr. Opin. Support. Palliat. Care 2011 , 5 , 233–240. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Weinstein, R.S.; Roberson, P.K.; Manolagas, S.C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N. Engl. J. Med. 2009 , 360 , 53–62. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Huang, X.; Hou, Y.; Weng, X.; Pang, W.; Hou, L.; Liang, Y.; Wang, Y.; Du, L.; Wu, T.; Yao, M.; et al. Diethyldithiocarbamate-copper complex (CuET) inhibits colorectal cancer progression via miR-16-5p and 15b-5p/ALDH1A3/PKM2 axis-mediated aerobic glycolysis pathway. Oncogenesis 2021 , 10 , 4. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Suh, J.J.; Pettinati, H.M.; Kampman, K.M.; O’Brien, C.P. The status of disulfiram: A half of a century later. J. Clin. Psychopharmacol. 2006 , 26 , 290–302. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Kannappan, V.; Ali, M.; Small, B.; Rajendran, G.; Elzhenni, S.; Taj, H.; Wang, W.; Dou, Q.P. Recent advances in repurposing disulfiram and disulfiram derivatives as copper-dependent anticancer agents. Front. Mol. Biosci. 2021 , 8 , 741316. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Guo, W.; Wang, H.; Chen, P.; Shen, X.; Zhang, B.; Liu, J.; Peng, H.; Xiao, X. Identification and characterization of multiple myeloma stem cell-like cells. Cancers 2021 , 13 , 3523. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Jin, N.; Zhu, X.; Cheng, F.; Zhang, L. Disulfiram/copper targets stem cell-like ALDH+ population of multiple myeloma by inhibition of ALDH1A1 and Hedgehog pathway. J. Cell. Biochem. 2018 , 119 , 6882–6893. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Chai, J.-Y.; Jung, B.-K.; Hong, S.-J. Albendazole and mebendazole as anti-parasitic and anti-cancer agents: An update. Korean J. Parasitol. 2021 , 59 , 189–225. [ Google Scholar ] [ CrossRef ] [ PubMed ]
- Wang, L.-J.; Lee, Y.-C.; Huang, C.-H.; Shi, Y.-J.; Chen, Y.-J.; Pei, S.-N.; Chou, Y.-W.; Chang, L.-S. Non-mitotic effect of albendazole triggers apoptosis of human leukemia cells via SIRT3/ROS/p38 MAPK/TTP axis-mediated TNF-α upregulation. Biochem. Pharmacol. 2019 , 162 , 154–168. [ Google Scholar ] [ CrossRef ] [ PubMed ]
Click here to enlarge figure
Purpose | Resource | Refs. |
---|
Human pathways and protein–protein interaction (PPI) | BiGRID, STRING, HAPPI, KEGG, Reactome | [ , , , , ] |
Molecular classification of more than 20,000 main cancers matched normal tissue from 33 types of cancer | Cancer Genome Atlas | [ ] |
Protein expression in cancer, matched normal tissues, and human cancer cell lines | The Human Protein Atlas | [ , , ] |
Drug sensitivity, gene expression, and genotype for human cancer cell lines | Cancer Cell Line Encyclopedia | [ ] |
Data of genome-wide transcription expression from cultured human cancer cells with many small compounds | Connectivity Map 02 (CMap) | [ , ] |
Disease-specific gene curation and analysis | OMIM, GEO | [ , ] |
Disease–disease connectivity; connectivity of two genes elaborated within the same disease | The human disease network | [ ] |
Disease similarities as seen through the lens of gene regulatory mechanisms; comprehension of disease etiology and pathophysiology | Human Disease Network Database (DNetDB) | [ ] |
Drug–drug interaction; comprehensive drug-target information on tens of thousands of drugs and targets | DrugBank | [ ] |
Drug–drug interaction | SFINX | [ ] |
Database of more than 270 non-cancer drugs for potential repurposing for anti-cancer therapy | Repurposing Drugs in Oncology (ReDO) | [ ] |
Database of drugs and adverse drug reactions (ADRs) | Side Effect Resource (SIDER) | [ ] |
Withdrawn or discontinued drugs | WITHDRAWN | [ , ] |
An inventory of main and secondary uses for repurposed pharmaceuticals | RepurposeDB | [ ] |
Chemical (including drugs)–protein interaction network | STITCH | [ ] |
Data on the sensitivity of hundreds of compounds and over a thousand cancer cell lines | Genomics of Drug Sensitivity in Cancer (GDSC) | [ ] |
Gene expression pattern-based prediction of drug effectiveness against cancer | DeSigN | [ ] |
Drug Name | Old-Indication | New-Indication | Mechanism of Action | Clinical Trials Status | Refs. |
---|
Thalidomide | Sedative, anti-nausea | MM | Inhibits IKK (also NF-κB); inhibits TNF; inhibits IL-1, IL-6, IL-12, VEGF | Approved in combination with dexamethasone | [ , ] |
Statins | High Cholesterol | MM | HMG-CoA reductase inhibitors, upregulation of PUMA and NOXA | Smouldering MM, phase II | [ , , , ] |
Celecoxib | Anti- inflammatory | MM and drug-resistant MM | Inhibits COX-2, inhibits Mcl-1, Bcl-2, survivin, Akt | Not for MM, approved for FAP | [ , , ] |
Aspirin | Anti- inflammatory | MM | Inhibits COX-1 and COX-2, suppresses cytokines and NF-κB, inhibits EKR and Blimp1, activates ATF4/CHOP | Preclinical | [ , ] |
Artesunate | Malaria | MM and drug-resistant MM | Decreased expression of MYC and Bcl-2, triggers cleavage of caspase-3 | Preclinical | [ , , , ] |
Leflunomide | Rheumatism | MM | DHODH inhibitor, cyclin D2 and pRb inhibition | Phase II
| [ , ] |
Clarithromycin | Antibiotic | MM and drug-resistant MM | Inhibits IL-6 and MGFs | Phase III | [ , ] |
Rapamycin | Fungal infections | MM | Antagonist of mTOR | Phase I | [ , , , ] |
Valproic acid | Seizures, migraine, and epilepsy | MM | Blocks HDAC, inhibits NF-κB and cytokines | Preclinical | [ ] |
Nelfinavir | HIV Infection | MM and drug-resistant MM | Inhibits 26S proteasome- disrupts Akt and STAT3, ERK1/2 | Phase I | [ , , , ] |
Metformin | Diabetes mellitus type 2 | MM | Activates AMPK (suppresses mTORC1, activates p53), inhibits EMT, regulates cell cycle proteins (ERK1/2, JAK2/STAT), IL-6 suppression | Smoldering Myeloma and Monoclonal gammopathy of undetermined significance phase II, MM phase I | [ , , , ] |
Bisphosphonates | Osteoporosis | MM | HMG-CoA pathway suppression, osteoclast apoptosis | Preclinical | [ , ] |
CuET | Alcohol-abuse drug disulfiram (DSF) | Drug-resistant MM | ALDH inhibition | Preclinical | [ ] |
Albendazole | Parasitic infections | Drug-resistant MM | Microtubule system interference, p65/NF-κB pathway inhibition | Preclinical | [ ] |
| The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
Share and Cite
Al-Odat, O.S.; Nelson, E.; Budak-Alpdogan, T.; Jonnalagadda, S.C.; Desai, D.; Pandey, M.K. Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma Patients. Cancers 2024 , 16 , 2381. https://doi.org/10.3390/cancers16132381
Al-Odat OS, Nelson E, Budak-Alpdogan T, Jonnalagadda SC, Desai D, Pandey MK. Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma Patients. Cancers . 2024; 16(13):2381. https://doi.org/10.3390/cancers16132381
Al-Odat, Omar S., Emily Nelson, Tulin Budak-Alpdogan, Subash C. Jonnalagadda, Dhimant Desai, and Manoj K. Pandey. 2024. "Discovering Potential in Non-Cancer Medications: A Promising Breakthrough for Multiple Myeloma Patients" Cancers 16, no. 13: 2381. https://doi.org/10.3390/cancers16132381
Article Metrics
Article access statistics, further information, mdpi initiatives, follow mdpi.
![MDPI Open Access Journals MDPI](https://pub.mdpi-res.com/img/design/mdpi-pub-logo-white-small.png?71d18e5f805839ab?1719563568)
Subscribe to receive issue release notifications and newsletters from MDPI journals
![stages in literature review process U.S. flag](https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png)
An official website of the United States government
The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
- Publications
- Account settings
- My Bibliography
- Collections
- Citation manager
Save citation to file
Email citation, add to collections.
- Create a new collection
- Add to an existing collection
Add to My Bibliography
Your saved search, create a file for external citation management software, your rss feed.
- Search in PubMed
- Search in NLM Catalog
- Add to Search
Inverted Classroom Teaching of Physiology in Basic Medical Education: Bibliometric Visual Analysis
Affiliations.
- 1 School of Basic Medicine and Public Health, Jinan University, Guangzhou, China.
- 2 Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, HKSAR, China.
- 3 Gies College of Business, University of Illinois Urbana-Champaign, Urbana-Champaign, IL, United States.
- 4 School of Education, South China Normal University, Guangzhou, China.
- PMID: 38940629
- DOI: 10.2196/52224
Background: Over the last decade, there has been growing interest in inverted classroom teaching (ICT) and its various forms within the education sector. Physiology is a core course that bridges basic and clinical medicine, and ICT in physiology has been sporadically practiced to different extents globally. However, students' and teachers' responses and feedback to ICT in physiology are diverse, and the effectiveness of a modified ICT model integrated into regular teaching practice in physiology courses is difficult to assess objectively and quantitatively.
Objective: This study aimed to explore the current status and development direction of ICT in physiology in basic medical education using bibliometric visual analysis of the related literature.
Methods: A bibliometric analysis of the ICT-related literature in physiology published between 2000 and 2023 was performed using CiteSpace, a bibliometric visualization tool, based on the Web of Science database. Moreover, an in-depth review was performed to summarize the application of ICT in physiology courses worldwide, along with identification of research hot spots and development trends.
Results: A total of 42 studies were included for this bibliometric analysis, with the year 2013 marking the commencement of the field. University staff and doctors working at affiliated hospitals represent the core authors of this field, with several research teams forming cooperative relationships and developing research networks. The development of ICT in physiology could be divided into several stages: the introduction stage (2013-2014), extensive practice stage (2015-2019), and modification and growth stage (2020-2023). Gopalan C is the author with the highest citation count of 5 cited publications and has published 14 relevant papers since 2016, with a significant surge from 2019 to 2022. Author collaboration is generally limited in this field, and most academic work has been conducted in independent teams, with minimal cross-team communication. Authors from the United States published the highest number of papers related to ICT in physiology (18 in total, accounting for over 43% of the total papers), and their intermediary centrality was 0.24, indicating strong connections both within the country and internationally. Chinese authors ranked second, publishing 8 papers in the field, although their intermediary centrality was only 0.02, suggesting limited international influence and lower overall research quality. The topics of ICT in physiology research have been multifaceted, covering active learning, autonomous learning, student performance, teaching effect, blended teaching, and others.
Conclusions: This bibliometric analysis and literature review provides a comprehensive overview of the history, development process, and future direction of the field of ICT in physiology. These findings can help to strengthen academic exchange and cooperation internationally, while promoting the diversification and effectiveness of ICT in physiology through building academic communities to jointly train emerging medical talents.
Keywords: academic; academic community; bibliometric; bibliometric analysis; bibliometric visual analysis; classroom-based; evolution trend; flipped classroom; flipped classroom teaching; frontier progress; hot topics; inverted classroom; medical education; physiology; scientific knowledge map; teaching method; visual analysis; visualization tool.
© Zonglin He, Botao Zhou, Haixiao Feng, Jian Bai, Yuechun Wang. Originally published in JMIR Medical Education (https://mededu.jmir.org).
PubMed Disclaimer
Similar articles
- Bibliometric study of immunotherapy for hepatocellular carcinoma. Li Z, Zhang Y, Zhang B, Guo R, He M, Liu ZL, Yang L, Wang H. Li Z, et al. Front Immunol. 2023 Aug 4;14:1210802. doi: 10.3389/fimmu.2023.1210802. eCollection 2023. Front Immunol. 2023. PMID: 37600802 Free PMC article. Review.
- The effects of flipped classrooms to improve learning outcomes in undergraduate health professional education: A systematic review. Naing C, Whittaker MA, Aung HH, Chellappan DK, Riegelman A. Naing C, et al. Campbell Syst Rev. 2023 Jul 7;19(3):e1339. doi: 10.1002/cl2.1339. eCollection 2023 Sep. Campbell Syst Rev. 2023. PMID: 37425620 Free PMC article. Review.
- School-based interventions for reducing disciplinary school exclusion: a systematic review. Valdebenito S, Eisner M, Farrington DP, Ttofi MM, Sutherland A. Valdebenito S, et al. Campbell Syst Rev. 2018 Jan 9;14(1):i-216. doi: 10.4073/csr.2018.1. eCollection 2018. Campbell Syst Rev. 2018. PMID: 37131379 Free PMC article.
- Knowledge domain, research hotspots and frontiers in physiology teaching reforms from 2012 to 2021: A bibliometric and knowledge-map analysis. Xu J, Sun S, Zhao Y, Ma Q. Xu J, et al. Front Med (Lausanne). 2023 Mar 20;10:1031713. doi: 10.3389/fmed.2023.1031713. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37020677 Free PMC article.
- Research Trends in the Application of Artificial Intelligence in Oncology: A Bibliometric and Network Visualization Study. Wu T, Duan Y, Zhang T, Tian W, Liu H, Deng Y. Wu T, et al. Front Biosci (Landmark Ed). 2022 Aug 31;27(9):254. doi: 10.31083/j.fbl2709254. Front Biosci (Landmark Ed). 2022. PMID: 36224012
- Search in MeSH
LinkOut - more resources
Full text sources.
- JMIR Publications
- Citation Manager
NCBI Literature Resources
MeSH PMC Bookshelf Disclaimer
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
![](//rss3.fun/777/templates/cheerup/res/banner1.gif)
IMAGES
VIDEO
COMMENTS
Literature Review and Research Design by Dave Harris This book looks at literature review in the process of research design, and how to develop a research practice that will build skills in reading and writing about research literature--skills that remain valuable in both academic and professional careers. Literature review is approached as a process of engaging with the discourse of scholarly ...
A literature review is an integrated analysis-- not just a summary-- of scholarly writings and other relevant evidence related directly to your research question.That is, it represents a synthesis of the evidence that provides background information on your topic and shows a association between the evidence and your research question.
In writing the literature review, your purpose is to convey to your reader what knowledge and ideas have been established on a topic, and what their strengths and weaknesses are. As a piece of writing, the literature review must be defined by a guiding concept (e.g., your research objective, the problem or issue you are discussing, or your ...
Examples of literature reviews. Step 1 - Search for relevant literature. Step 2 - Evaluate and select sources. Step 3 - Identify themes, debates, and gaps. Step 4 - Outline your literature review's structure. Step 5 - Write your literature review.
This article is organized as follows: The next section presents the methodology adopted by this research, followed by a section that discusses the typology of literature reviews and provides empirical examples; the subsequent section summarizes the process of literature review; and the last section concludes the paper with suggestions on how to improve the quality and rigor of literature ...
Step One: Decide on your areas of research: Before you begin to search for articles or books, decide beforehand what areas you are going to research. Make sure that you only get articles and books in those areas, even if you come across fascinating books in other areas. A literature review I am currently working on, for example, explores ...
The first step in the process involves exploring and selecting a topic. You may revise the topic/scope of your research as you learn more from the literature. Be sure to select a topic that you are willing to work with for a considerable amount of time. ... A literature review must include a thesis statement, which is your perception of the ...
In writing the literature review, your purpose is to convey to your reader what knowledge and ideas have been established on a topic, and what their strengths and weaknesses are. As a piece of writing, the literature review must be defined by a guiding concept (e.g., your research objective, the problem or issue you are discussing, or your ...
Select a topic you can manage in the time frame you have to complete your project.; Establish your research questions and organize your literature into logical categories around the subject/ topic areas of your questions.Your research questions must be specific enough to guide you to the relevant literature.; Make sure you understand the concept of 'broader' and 'narrower' terms.
Here is a general outline of steps to write a thematically organized literature review. Remember, though, that there are many ways to approach a literature review, depending on its purpose. Stage one: annotated bibliography. As you read articles, books, etc, on your topic, write a brief critical synopsis of each.
Introduction to Research Process: Literature Review Steps. When seeking information for a literature review or for any purpose, it helps to understand information-seeking as a process that you can follow. 5 Each of the six (6) steps has its own section in this web page with more detail. Do (and re-do) the following six steps: ...
Literature Review. The structure of a literature review should include the following: An overview of the subject, issue or theory under consideration, along with the objectives of the literature review, Division of works under review into themes or categories (e.g. works that support of a particular position, those against, and those offering ...
A Systematic Literature Review (SLR) is a research methodology to collect, identify, and critically analyze the available research studies (e.g., articles, ... By process phases, stages: When analyzing a process or series of processes, an effective way to structure the data is to find a well-established framework of reference or architecture.
A formal literature review is an evidence-based, in-depth analysis of a subject. There are many reasons for writing one and these will influence the length and style of your review, but in essence a literature review is a critical appraisal of the current collective knowledge on a subject. Rather than just being an exhaustive list of all that ...
literature review process. While reference is made to diflFerent types of literature reviews, the focus is on the traditional or narrative review that is undertaken, usually either as an academic assignment or part of the research process. Key words: Aneilysis and synthesis • Literature review • Literature searching • Writing a review T
Remember, the literature review process is iterative. For more detailed information on forming and evaluating research questions, see these books available to order through ILL from OhioLINK. ... Note: This stage in the literature review process is as iterative and personal as any other. These steps offer a guideline, but do what works for you ...
A literature review is a comprehensive summary of previous research on a topic. ... New and improved graphics ideal for visualizing the process More explanations and tips, especially for writing in the early stages An expanded range of learning tools Additional reflection sections to direct metacognitive activities Four new reference ...
Literature reviews play a critical role in scholarship because science remains, first and foremost, a cumulative endeavour (vom Brocke et al., 2009). As in any academic discipline, rigorous knowledge syntheses are becoming indispensable in keeping up with an exponentially growing eHealth literature, assisting practitioners, academics, and graduate students in finding, evaluating, and ...
The process of writing a literature review. Writing a literature review is a non-linear and iterative process. This means you'll be revisiting the different stages of developing your review. There are four stages in conducting a literature review. Click on each stage below for tips on the different strategies used to conduct the literature ...
Step 8: The literature review in your thesis. This last step reveals what criteria are used to evaluate the literature review in your own thesis: synthesis, critical appraisal, and application to the research question. I also explain what your literature should not look like and why a good literature review helps you to get papers published.
Image by TraceyChandler. Steps to conducting a systematic review. Quick overview of the process: Steps and resources from the UMB HSHSL Guide. YouTube video (26 min); Another detailed guide on how to conduct and write a systematic review from RMIT University; A roadmap for searching literature in PubMed from the VU Amsterdam; Alexander, P. A. (2020).
Research Guides: Writing a Literature Review: 6 Stages to Writing a Literature Review
The process of systematic literature review, underlying the search for and analysis of the existing divisions of knowledge-based and ICT networks, was carried out in three stages (Anello & Fleiss ...
A systematic literature review was conducted to investigate the literature on Lean, Green and Industry 4.0. ... approach for SLR. The SLR was carried out in 6 stages: the Planning Review, literature search method, defining inclusion and exclusion criteria, a quality assessment and review, and finally, conducting the review and analysis ...
Setting the stage for the fall. The first debate during the 2020 election cycle was in early September, meaning the first 2024 general election debate was significantly earlier than usual — more ...
IR-2024-169, June 20, 2024 — Following a detailed review to protect taxpayers and small businesses, the Internal Revenue Service today announced plans to deny tens of thousands of improper high-risk Employee Retention Credit claims while starting a new round of processing lower-risk claims to help eligible taxpayers.
MM is a common type of cancer that unfortunately leads to a significant number of deaths each year. The majority of the reported MM cases are detected in the advanced stages, posing significant challenges for treatment. Additionally, all MM patients eventually develop resistance or experience relapse; therefore, advances in treatment are needed. However, developing new anti-cancer drugs ...
The SLR process is divided into several stages, including: Identifying articles based on the title, abstract, and keywords related to 'policy politics; social entrepreneurship; infrastructure violence. ... Systematic Literature Review (SLR) of entrepreneurship policies by political communities explains that community entrepreneurship policies ...
This bibliometric analysis and literature review provides a comprehensive overview of the history, development process, and future direction of the field of ICT in physiology. ... The development of ICT in physiology could be divided into several stages: the introduction stage (2013-2014), extensive practice stage (2015-2019), and modification ...
With reference to article 21.03, the results of the third-placed teams are compared based on their three group stage matches, according to the following criteria: